Abstract
Objective: Beyond BRCA1/2, a number of genes are associated with an increased risk for ovarian and/or other cancers. The majority of these genes have associated National Comprehensive Cancer Network (NCCN) guidelines for cancer risk management. We aimed to determine the frequency of pathogenic germline mutations in genes, other than BRCA1/2, among women with ovarian cancer undergoing multigene panel testing (MGPT).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
